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Circulating tumour cells (CTC) and tumour-related methylated DNA in blood have been separately assessed for their utility as a
marker for subclinical metastasis in breast cancer. However, no studies have looked into the relation between the both molecular
markers in this type of cancer. In this study, we investigated the correlations between total/methylated DNA and CTC in the blood
from metastatic breast cancer patients. We simultaneously obtained whole blood, plasma and serum samples from 80 patients and
20 controls. The CellSearch System was used to enumerate CTC in blood samples. Plasma total DNA levels were determined by a
QPCR method. Sera were analysed by methylation-specific QPCR for three markers: adenomatous polyposis coli (APC), ras association
domain family protein 1A (RASSF1A) and oestrogen receptor 1 (ESR1). Total DNA levels in patients were significantly increased when
compared with controls (Po0.001) and correlated with the number of CTC (r¼0.418, Po0.001). Hypermethylation of one or
more genes was detected in 42 (53%) serum samples from breast cancer patients and in three (16%) serum samples from controls
(P¼0.003). APC was hypermethylated in 29%, RASSF1A in 35% and ESR1 in 20% of breast cancer cases. Detection of a methylated
gene in serum was associated with the detection of CTC in blood (P¼0.03). The detection of large amounts of circulating total/
methylated DNA correlated with the presence of CTC in the blood from patients with breast cancer. This can be interpreted in two
ways: (a) CTC are a potential source of circulating tumour-specific DNA; (b) high numbers of CTC and circulating methylated DNA
are both a phenotypic feature of more aggressive tumour biology.
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Distant metastasis is the leading cause of cancer-related death in
breast cancer, but early spread of tumour cells usually remains
undetected even by high-resolution imaging technologies. With the
use of traditional prognostic factors, it is still not possible to
reliably identify those breast cancer patients who will eventually
relapse with metastatic disease and are in need of adjuvant
therapy. Therefore, the development of new molecular staging
methods enabling individual risk assessment is of utmost
importance. As haematogenous dissemination of tumour cells is
the main mechanism for distant metastasis, the assessment of
cancer patients’ blood may be a highly desirable approach for
detecting systemic tumour cell spreading (Pantel et al, 1999).
Several studies have suggested that the presence of circulating
tumour cells (CTC) in patients’ bone marrow or blood represents a
promising marker for current risk classification systems for breast
cancer. Recently, we showed that the presence of CK19þ
disseminated tumour cells in the bone marrow by reverse
transcriptase–PCR is an independent prognostic factor in
untreated patients with breast cancer (Benoy et al, 2006).
Moreover, a pooled analysis involving 4703 patients indicated that
the presence of micrometastasis in the bone marrow at the time of
diagnosis of breast cancer is an independent predictor of poor
prognosis (Braun et al, 2005). CTC detection by the CellSearch
System (Veridex LLC, Warren, NJ, USA), developed to auto-
matically enrich and immunocytochemically detect CTC from
peripheral blood, has been shown to provide significant prognostic
information for patients with metastatic breast cancer starting
first-line therapy (Cristofanilli et al, 2004, 2005). In latter studies,
the persistence of CTC at 3 to 4 weeks after the treatment was
started and at the time of restaging continued to be significantly
associated with prognosis, particularly in women with hormone
receptor-negative disease and women who were receiving
chemotherapy.
Epigenetic changes, such as DNA methylation, are one of the
most common molecular alterations in human neoplasia (Egger
et al, 2004), including breast cancer (Widschwendter and Jones,
2002). DNA methylation refers to the addition of a methyl group to
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sthe cytosine ring of those cytosines that precede a guanosine
(referred to as CpG dinucleotides) to form 5-methylcytosine. CpG
dinucleotides are found at increased frequency in the promoter
region of many genes, and methylation in the promoter regions is
frequently associated with gene silencing (Leonhardt and Cardoso,
2000). Several studies have shown that tumour-specific epigenetic
alterations can be detected in DNA recovered from plasma or
serum of patients with various malignancies (Wong et al, 1999;
Silva et al, 1999a; Sanchez-Cespedes et al, 2000), a finding that may
be of particular clinical interest in view of molecular diagnosis and
prognosis. Increased concentrations of free DNA are detected in the
blood of many cancer patients, whereas only small amounts of free
circulating DNA are found in healthy individuals (Leon et al, 1977).
The serum of breast cancer patients contains, on an average,
approximately four times more free DNA compared with that of
healthy individuals (Gal et al, 2004). Recently, investigators have
shown that hypermethylation of ras association domain family
protein 1A (RASSF1A) and/or adenomatous polyposis coli (APC)
identified in serum DNA from breast cancer patients is associated
with a worse outcome (Mu ¨ller et al, 2003). Furthermore, methylated
RASSF1A and neurogenic differentiation 1 gene promoters in serum
are candidate biomarkers for monitoring the efficacy of adjuvant
therapy in breast cancer patients (Fiegl et al, 2005, 2008).
The precise mechanism by which DNA is released into the
bloodstream still remains enigmatic. The most common hypo-
thesis advanced for circulating DNA in the blood of cancer patients
is that it is because of the lysis of CTC (Stroun et al, 2000). Other
possible sources include DNA leakage from cells as the result of
tumour necrosis or apoptosis, or spontaneous release of DNA into
the circulation from primary and metastatic tumours (Stroun et al,
2000). Although many studies have suggested the usefulness of
CTC or cell-free DNA as a surrogate marker of subclinical
metastasis for breast cancer (Taback et al, 2001; Huang et al,
2006; Ntoulia et al, 2006; Wong et al, 2006; Wu ¨lfing et al, 2006;
Xenidis et al, 2006; Quintela-Fandino et al, 2006), few studies have
looked into the relation between CTC and cell-free DNA in this
type of cancer (Schwarzenbach et al, 2004). A combined molecular
assessment of the circulating DNA and CTC could improve the
evaluation of cancer stage and overall prognosis in breast cancer.
The aim of this study was to identify tumour-specific epigenetic
alterations in the cell-free DNA found in the peripheral blood of
breast cancer patients and to assess whether a correlation exists
between total or tumour-specific methylated DNA and the
detection of CTC in peripheral blood of patients with metastatic
breast cancer. We decided to investigate these molecular markers
in women with metastatic disease because CTC and the circulating
DNA levels are known to be higher in these patients.
MATERIALS AND METHODS
Patients and sample collection
We prospectively obtained matched peripheral blood, serum and
plasma samples from 80 patients with breast cancer and 20 healthy
volunteers. All patients gave informed consent for the use of their
blood specimen and the examination of blood samples was carried
out after approval from the Institutional Review Board of the
General Hospital Sint-Augustinus (Wilrijk, Belgium). The patient
population consisted of four patients with localised breast cancer
(group A), 60 patients with metastatic breast cancer receiving
treatment (group B) and 16 patients presenting in our clinic with
untreated metastatic breast cancer (group C). Clinicopathological
variables are listed in Table 1. The median age of the control
population was 39 (range, 25–54) years and 62 (range, 34–85)
years in the breast cancer population.
Blood samples from patients with metastatic disease were taken
during the course of treatment. Disease status was assessed using
the RECIST (Response Evaluation Criteria in Solid Tumours
Group) criteria without the knowledge of the patients’ CTC or
circulating DNA results (Therasse et al, 2000). Stable disease was
measured up to 8 weeks after the initiation of therapy.
In 18 cases, the corresponding breast cancer tissue samples were
available for analysis. All tumour tissues were obtained immedi-
ately after surgical resection and snap frozen in liquid nitrogen.
Quantitative analysis of total DNA
Blood (4.5ml) from each donor was collected in 0.129M sodium
citrate-containing tubes (Becton Dickinson, Franklin Lakes, NJ,
USA) and centrifuged (2000g, 10min) at room temperature. Then,
plasma was aliquotted and cryopreserved at  801C until use. DNA
was extracted from 200ml of plasma using the JETQUICK Blood
and Cell Culture Kit (Genomed, Lo ¨hne, Germany) according to the
manufacturer’s protocol, with an elution volume of 100ml. Plasma
DNA concentration was measured by a real-time quantitative PCR
assay for the human telomerase reverse transcriptase gene using
the Quantifiler Human DNA Quantification Kit (Applied Biosystems,
Foster City, CA, USA). The assay included two primers and a
FAM-labelled fluorescent TaqMan probe for the target gene, and
two primers and a VIC-labelled fluorescent TaqMan probe for an
internal control DNA sequence. For construction of the calibration
curve, we generated a standard curve using three-fold serial
dilutions of known concentrations of DNA (50, 16.67, 5.56, 1.85,
0.62, 0.21 and 0.023ngml
–1). PCR was carried out in a final
reaction volume of 25ml and contained 12.5ml of Quantifiler PCR
Reaction Mix (Applied Biosystems), 10.5ml of Quantifiler Human
Primer Mix (Applied Biosystems) and 2ml of extracted DNA. Each
sample was analysed in duplicate.
Table 1 Frequency of methylated genes (% positives) according to
clinicopathological features
Variables
Number of
patients APC RASSF1A ESR1
At least
one gene
methylated
ER
Positive 53 36 47* 19 62*
Negative 22 18 14 23 36
PR
Positive 38 32 42 16 58
Negative 35 31 34 26 54
HR
Positive 52 37 48* 19 63*
Negative 21 19 14 24 38
HER2
Positive 26 35 31 15 58
Negative 52 27 38 21 50
Triple negative
Positive 10 20 20 20 30
Negative 63 33 41 21 60
p53
Positive 18 39 33 22 55
Negative 33 33 45 24 70
Disease status
PD 46 39 52* 26 67*
SD 26 19 12 15 38
Abbreviations: APC¼adenomatous polyposis coli; ESR1¼oestrogen receptor 1;
HR¼hormone receptor; PD¼progressive disease; RASSF1A¼ras association
domain family protein 1A; SD¼stable disease. *P-values p0.05.
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sThe mean quantity of each duplicate calculated by the 7900
sequence detection system software was used for further analysis.
The concentration, expressed in nanograms per millilitre, was
calculated using the following equation: C¼Q VDNA/VPCR 
1/Vext 1000, where C¼target concentration in plasma
(nanograms per millilitre); Q¼target quantity (nanograms);
VDNA¼total volume of extraction (100ml); VPCR¼volume of
DNA solution used per PCR reaction (2ml); and Vext¼volume of
plasma extracted (200ml).
Methylated DNA assay
Blood (8ml) from each donor was collected in serum separator
tubes (Becton Dickinson) and centrifuged (2000g, 10min) at room
temperature. Then, serum was aliquotted and cryopreserved at
 801C until use. Genomic DNA was extracted from 1ml of serum
using the ZR Serum DNA Kit (Zymo Research, Orange, CA, USA),
with an elution volume of 35ml. Genomic DNA from frozen breast
cancer tissues was isolated using the QIAamp DNA Mini Kit
(Qiagen, Valencia, CA, USA). Sodium bisulphite conversion of
extracted DNA was conducted using the EZ DNA Methylation Kit
(Zymo Research). Sodium bisulphite-converted DNA was analysed
by real-time qMSP. Two sets of primers and probes, designed
specifically for sodium bisulphite-converted DNA, were used: a
methylated set for the genes of interest and a reference set, b-actin
(ACTB), to normalise for input DNA. Fluorogenic probes and PCR
primer sets for APC (Usadel et al, 2002), RASSF1A (Lehmann et al,
2002), oestrogen receptor 1 (ESR1) (Eads et al, 2001) and ACTB
(Eads et al, 2000) were custom synthesised by Applied Biosystems.
Fluorogenic PCRs were carried out in a reaction volume of 25mli n
96-well plates in a 7900HT Sequence Detector (Applied Biosystems).
PCR was carried out in separate wells for each primer/probe set,
and each sample was run in duplicate. The final reaction mixture
consisted of 600nmoll
–1 of each primer, 200nmoll
–1 of probe
and 12.5ml of Universal Master Mix (Applied Biosystems). Five ml
of the treated DNA solution was used in each real-time MSP
reaction. Thermal cycling was initiated with a first denaturation
step of 951C for 10min. The thermal profile for the PCR was 951C
for 15s and 601C for 1min. Data obtained during 50 cycles of
amplification were analysed. Each plate included water blanks, a
positive control and a negative control. DNA isolated from normal
peripheral lymphocytes from healthy individuals served as a
negative methylation control. In vitro methylated human DNA
(Zymo Research) was used as the positive methylation control.
The ratio between the values obtained in the two TaqMan
analyses was used as a measure for the degree of methylation of the
target gene. The percentage of fully methylated molecules at a gene
locus was calculated by dividing the gene:ACTB ratio of a sample
by the gene:ACTB ratio of fully methylated human DNA and
multiplying by 100. We use the abbreviation percentage of
methylated reference (PMR) to indicate this measurement. A gene
was deemed methylated if the PMR value was 40.
CTC assay
Peripheral blood (10ml) was collected from each donor into
CellSave blood collection tubes (Immunicon Inc., Huntingdon
Valley, PA, USA), which are evacuated blood-draw tubes containing
EDTA and a cellular preservative, and processed within a maximum
of 72h after blood drawing (at room temperature).
Circulating tumour cells were enumerated with the CellSearch
System (Veridex, Warren, NJ, USA) as described by Allard et al
(2004). Briefly, 7.5ml of blood were gently mixed with 6.5ml of
dilution buffer, centrifuged (800 g, 10min, gentle deceleration)
at room temperature and transferred into the CellTracks AutoPrep
system (Veridex, Warren, NJ, USA). After aspiration of the plasma
and dilution buffer layer, anti-EpCAM antibody-coated ferrofluids
were added. After incubation and magnetic separation, unbound
cells and remaining plasma were removed, and ferrofluid-labelled
cells were re-suspended in buffer, permeabilised, and fluorescently
labelled using phycoerythrin-conjugated anti-cytokeratin anti-
bodies recognising cytokeratins (predominantly cytokeratins 8,
18 and 19) to specifically identify epithelial cells, an antibody
against CD45 conjugated with allophycocyanin to identify WBC
and a nuclear dye (40,6-diamidino-2-phenylindole (DAPI)) to
fluorescently label the cell nuclei. The sample was transferred
automatically to a cartridge in a MagNest (Veridex, Warren, NJ,
USA), where the immunomagnetically labelled cells move to the
surface caused by the strong magnetic field of the MagNest device.
The MagNest was placed on the CellTracks Analyzer II (Veridex,
Warren, NJ, USA), a four-color semi-automated fluorescence
microscope, and image frames covering the entire surface
of the cartridge for each of the four fluorescent filter cubes were
captured. The captured images containing objects that met pre-
determined criteria were automatically presented in a web-enabled
browser from which final selection of cells was made by the
operator. The main criteria for an object to be defined as a CTC
included round to oval morphology, a visible nucleus (DAPI
positive), positive staining for cytokeratin and negative staining for
CD45. Results of cell enumeration were expressed as the number of
cells per 7.5ml of blood, and a cutoff of X2 CTC was chosen to
define the test as positive. Each sample was analysed independently
by two readers (HJ Elst and PB Vermeulen). Questionable
interpretations were evaluated again until consensus was reached.
Statistical analysis
We used Pearson’s w
2 or, in the case of low frequencies per cell,
Fisher’s exact method to test associations between categorical
variables. The Mann–Whitney U-test or the Kruskal–Wallis test
was used to assess the differences between non-parametric
distributed variables. A two-sided Pp0.05 was considered to be
statistically significant. All statistical calculations were carried out
using SPSS, version 11.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
Total DNA concentrations in plasma from healthy
volunteers and breast cancer patients
The median concentration of plasma DNA in the healthy controls
(n¼20) was 4ngml
–1 (range 0–17ngml
–1). The median value
for breast cancer patients (n¼80) was 13ngml
–1 (range
2–2027ngml
–1). The median values and ranges for the different
groups of breast cancer patients were as follows: 7 (4–12)ngml
–1
for group A (n¼4), 12 (2–123)ngml
–1 for group B (n¼60) and
29 (4–2027)ngml
–1 for group C (n¼16) (Figure 1). The
difference between the patients and the controls was statistically
significant (Po0.001). Differences between plasma DNA concen-
trations in different patients groups also reached statistical
significance (P¼0.04). The largest differences were measurable
between groups A and C (P¼0.02) and groups B and C (P¼0.06).
The plasma DNA levels were significantly correlated with
CA15.3 levels (r¼0.276, P¼0.02) and tended to be correlated
with tumour progression, although this was not statistically signifi-
cant: median total DNA levels were 11 (range, 3–94)ngml
–1 in
patients with stable disease (n¼27) and 20 (range, 2–2027)ngml
–1
in patients with progressive disease (n¼46) (P¼0.09). Plasma
DNA concentrations were positively associated with patient age
(r¼0.298, P¼0.007). No associations with ER, PR, HER2 and p53
were found.
Receiver-operating characteristics (ROC) curve analysis was
carried out to define cutoff DNA levels for the prediction of
malignancy (Figure 2). The area under the ROC curve assessing
plasma DNA concentration was 0.865 (95% confidence interval,
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molecular assay. Table 2 lists several cut-off points of DNA values
used for the generation of the ROC curve with their sensitivity and
specificity. The highest accuracy was obtained at the cut-off point
of 8.275ngml
–1 with a sensitivity of 72.5% and a specificity of
85%. We divided patients into high plasma DNA level group
(HDNA) and low plasma DNA level group (LDNA) according to
the cut-off value identified in the ROC curve analysis. Overall, 85%
of patients with progressive disease were in the HDNA group,
whereas there were only 59% with stable disease in the HDNA
group (P¼0.01) (Table 3a). Again, no associations were found
with ER, PR, HER2 and p53.
Detection of tumour-related methylated DNA in serum
We selected a panel of three genes, namely, APC, RASSF1A and
ESR1, for the detection of tumour-specific methylated DNA in
serum samples from healthy controls (n¼19) and breast cancer
patients (n¼79). Median PMR values of APC and RASSF1A, but
not of ESR1, were significantly higher among breast cancer cases as
compared with controls (Po0.05). Methylation of APC was
positively associated with the methylation of RASSF1A (r¼0.372,
P¼0.001), but not with methylation of ESR1 (Figure 3). The
distribution of PMR in the patient and control groups is shown for
all three genes in Figure 4. PMR values of APC (r¼0.398,
P¼0.001), RASSF1A (r¼0.551, Po0.001), but not of ESR1
(r¼0.078, P¼0.52), were positively correlated with levels of the
tumour marker CA15.3. No associations were found between
PMR values of the three genes and age of the patient.
Detection of any level of aberrant methylation (PMR40)
resulted in a specificity for detecting breast cancer of 95% for
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Figure 1 Concentration of circulating DNA in the plasma of different
patient groups and controls. Median DNA concentrations are indicated on
the graph.
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Figure 2 Receiver-operating characteristics curve for plasma total DNA
concentration in 20 healthy individuals and 80 patients with breast cancer,
plotting the true positive rate (sensitivity) against the false positive rate
(1-specificity) for the different possible cut-off points. The area under the
curve was 0.865, suggesting a good discriminative power of the molecular
assay.
Table 2 Sensitivity and specificity of plasma DNA quantification assay
Cut-off points (ngml
–1) Sensitivity (%) Specificity (%)
6.1300 82.5 75
7.4700 76.3 80
8.2750 72.5 85
9.7350 65 90
12.2650 52.5 95
Table 3 Correlations of (a) plasma total DNA, (b) serum methylated
DNA, (c) CTC and (d) molecular markers
Response
(a) Total DNA levels
Stable
(n¼27)
Progressive
(n¼46) P-value
High 16 39 0.01
Low 11 7
(b) Methylated serum DNA
Stable
(n¼26)
Progressive
(n¼46)
Methylated 10 31 0.02
Unmethylated 16 15
(c) CTC
Stable
(n¼26)
Progressive
(n¼46)
Positive 5 22 0.02
Negative 21 24
(d) Molecular markers
Stable
(n¼25)
Progressive
(n¼46)
Negative 6 4 0.01
At least one marker positive 10 8
Two or more markers positive 7 18
Three markers positive 2 16
CTC¼circulating tumour cell.
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methylation in serum DNA of APC and RASSF1A was significantly
higher among women with breast cancer as compared with
controls: APC, 29 versus 5% (P¼0.03) and RASSF1A, 35 versus 0%
(P¼0.002). However, the association of methylation in serum
DNA of ESR1 with case status did not reach statistical significance:
ESR1 was hypermethylated in 20% of breast cancer patients and
10.5% of healthy controls (P¼0.33). Of the 79 patients with breast
cancer, 7 (9%) had all the three methylated markers, 18 (23%) had
at least two methylated markers and 42 (53%) had at least one
methylated marker in serum. Of all two-marker combinations, the
combination of APC and/or RASSF1A methylation was most
frequently observed, in 47% of breast cancer cases. Methylation of
multiple genes in serum DNA was not detected in any of the 19
controls. The difference in the number of methylated genes
between breast cancer patients and controls was statistically
significant (P¼0.003).
The detection of at least one methylated marker in serum
was associated with the disease status (P¼0.02) (Table 3b).
Hypermethylation of both APC and RASSF1A, but not of ESR1, was
more frequently detected in patients with progressive disease as
compared with patients with stable disease (P¼0.08 and P¼0.001,
respectively). Hypermethylation of RASSF1A was signi-
ficantly associated with ER expression (P¼0.01) and HR status
(P¼0.007), which was defined as positive if ER and/or PR were
positive (Table 2). No associations were found with PR status,
HER2 status, triple negative (ER–, PR– and HER2–) tumours and
p53 status. No significant associations were found between
hypermethylation of ESR1 and APC and any of the clinicopatho-
logical variables (Table 1). Although there were no statistically
significant differences in detection of aberrant methylation by age
among breast cancer patients, each gene was more likely to be
aberrantly methylated in older (460y) compared with younger
participants with breast cancer (Table 4).
In 18 cases, the corresponding breast cancer tissue samples were
available for analysis. ESR1 was methylated in all tissue samples,
whereas APC was unmethylated in one case and RASSF1A in three
cases. All of the genes found to be methylated in serum samples
were also methylated in the corresponding tissue sample.
Comparison of PMR values of breast cancer tissue samples between
unmethylated and methylated serum samples for each investigated
gene showed no significant results (Figure 5). Median PMR values
in, respectively, unmethylated and methylated serum samples were
72 (range, 0–143) and 125 (range, 1–361) for APC (P¼0.21), 12
(range, 0–63) and 48 (range, 1–67) for RASSF1A (P¼0.127) and
1.2 (range, 0.2–3.5) and 1.3 (range, 0.7–3.7) for ESR1 (P¼0.64).
Detection of CTC in peripheral blood
Overall, positive cells were identified in the blood of 65% of breast
cancer patients and 10% of controls (Figure 6). Numbers of CTC
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Figure 3 Correlations between methylation levels for the three genes. A significant correlation was observed between percentage of methylated
reference (PMR) values for adenomatous polyposis coli (APC) and ras association domain family protein 1A (RASSF1A)( C) and between PMR values for
RASSF1A and oestrogen receptor 1 (ESR1)( B). No clear correlation was observed between PMR values for APC and ESR1 (A).
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cancer than in healthy controls: the median number of CTC
detected in 7.5ml of blood was 1 (range, 0–2617) in breast cancer
patients and 0 (range 0–1) in controls (Po0.001). Numbers of CTC
also tended to differ between different patients groups, although
this was not statistically significant: no CTC were detected in group
A, the median number of CTC in group B was 1 (0–2617) and the
median number of CTC in group C was 0.5 (0–153) (P¼0.07). CTC
numbers by the CellSearch System were significantly correlated
with the patients’ age (r¼0.380, P¼0.001) and CA15.3 levels
(r¼0.685, Po0.001). Furthermore, the number of CTC tended to
be higher in ERþ breast tumours (P¼0.09) and HER2– breast
tumours (P¼0.08), although this was not statistically significant.
Using X2 cells as a threshold for positive samples in the patient
population, which corresponded to 100% specificity in the control
population, 34% of samples from patients were positive with the
CellSearch System. A significant association was observed between
CTC and tumour progression: in 22 of 46 (48%) patients with
progressive disease CTC were detected, whereas only in 5 of 26 (9%)
patients with stable disease CTC were present (P¼0.02) (Table 3c).
Association between CTC and total plasma DNA or serum
methylated DNA
The concentration of total DNA in plasma was significantly
correlated with the number of CTC detected in peripheral blood
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Figure 4 Methylation levels of (A) adenomatous polyposis coli (APC), (B) ras association domain family protein 1A (RASSF1A) and (C) oestrogen receptor 1
(ESR1) in serum DNA of healthy controls (n¼19) and breast cancer patients (n¼79). Differences in percentage of methylated reference (PMR) values
between patients and controls were examined with the Mann–Whitney U-test. For APC and RASSF1A significantly higher PMR values were observed in
patients versus controls (P¼0.04 and P¼0.003, respectively). For ESR1, differences in PMR values between patients and controls did not reach statistical
significance (P¼0.33).
Table 4 Aberrant methylation of genes by age
Age (years)
Genes o40 (n¼4) 40–49 (n¼14) 50–59 (n¼17) X60 (n¼44) P-value
APC 0 3 (13%) 4 (17%) 16 (70%) 0.33
RASSF1A 1 (4%) 5 (18%) 4 (14%) 18 (64%) 0.61
ESR1 0 5 (31%) 3 (19%) 8 (50%) 0.35
At least one gene methylated 1 (2%) 6 (14%) 8 (19%) 27 (64%) 0.35
Abbreviations: APC¼adenomatous polyposis coli; ESR1¼oestrogen receptor 1; RASSF1A¼ras association domain family protein 1A.
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s(r¼0.368, P¼0.001) (Figure 7). Patients with CTC in peripheral
blood had significantly higher plasma total DNA levels than
patients with no CTC: median DNA concentrations were,
respectively, 10 (range, 2–118)ngml
–1 and 31 (3–2027)ngml
–1
(P¼0.002) (Table 5a). PMR values for APC (r¼0.314, P¼0.005)
and RASSF1A (r¼0.492, Po0.001) were significantly correlated
with the number of CTC detected in peripheral blood. No
associations were found between PMR values for ESR1 and CTC.
In patients with at least one gene methylated in serum (n¼42),
CTC were detected in 19 (45%) cases. In patients without any
methylation in serum DNA (n¼36), no CTC were detected in 28
(78%) cases. Detection of a methylated gene in serum was
significantly associated with the detection of CTC in peripheral
blood (P¼0.03) (Table 5b). Also the number of methylated genes
in serum was significantly correlated with the presence of CTC in
paired specimens (P¼0.01).
CTC, total and/or methylated DNA as predictive markers
of tumour progression
Next, we evaluated the correlation of the three molecular markers
(high plasma total DNA, presence of CTC and methylated markers
in serum) with tumour progression. Overall, 18% of breast cancer
patients were positive for all the three molecular markers (high
plasma DNA, at least one methylated gene in serum and X2 CTC),
56% of breast cancer patients were positive for at least two
molecular markers, 82% of breast cancer patients were positive for
at least one molecular marker and 18% of breast cancer patients
were negative for all three markers. Of 19 healthy controls, 13
(68%) were negative for all three markers. The presence of multiple
markers was not detected in the control population.
Of all patients with stable disease (n¼25), two (8%) were positive
f o ra l lt h r e em a r k e r s ,n i n e( 3 6 % )w e r ep o s i t i v ef o rX2m a r k e r s ,1 9
(76%) were positive for at least one marker and six (24%) were
completely negative. In contrast, of all patients with progressive disease
(n¼46), 16 (35%) were positive for all the three markers, 34 (74%)
were positive for X2 markers, 42 (91%) were positive for at least one
marker and four (9%) were completely negative (P¼0.01) (Table 3d).
DISCUSSION
Circulating DNA is present in plasma in healthy controls and is
increased in cancer patients (Leon et al, 1977). These findings have
attracted much attention to the potential use of elevated
concentrations of circulating total DNA as a tumour marker. In
this study, we measured the level of circulating DNA in the plasma
of healthy controls and patients with localised or metastatic breast
cancer using a real-time quantitative PCR method. Our results
show a 3.25-fold difference in the median levels of circulating total
DNA in plasma between breast cancer patients and healthy
controls. The ROC curve result shows a good association between
high DNA concentration and malignancy. The range of total DNA
levels in the circulation of breast cancer patients varied widely,
from levels like those in the controls (2–17ngml
–1) to levels that
exceeded values of 2000ngml
–1 plasma. The highest values were
measured in patients presenting in our clinic with untreated
metastatic disease. Furthermore, total DNA levels tended to
correlate with the tumour serum marker CA15.3, which is a high
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Figure 5 Comparison of percentage of methylated reference (PMR) values in breast cancer tissue between unmethylated (negative) and methylated
(positive) serum samples for (A) adenomatous polyposis coli (APC), (B) ras association domain family protein 1A (RASSF1A) and (C) oestrogen receptor 1
(ESR1). Differences in PMR values between unmethylated and methylated serum samples were examined with the Mann–Whitney U-test. For none of the
genes did these differences reach statistical significance.
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smolecular glycoprotein (mucin) that can be detected in the
peripheral blood of breast cancer patients. Although in patients
with primary breast cancer the concentration of CA15.3 is usually
within the normal range, increased levels of CA15.3 are often
observed in patients with metastatic disease and correlate with an
increased metastatic load (Antoine et al, 1994).
Circulating nucleic acids harbouring tumour-specific alterations
have been identified in serum or plasma from breast cancer
patients (Silva et al, 1999a). Methylated DNA markers are
attractive tumour markers in blood for several reasons: (a) DNA
in blood is stable, is easy to obtain and can be analysed by a high-
throughput method such as qMSP; (b) methylated DNA markers
are frequently found in a wide range of human cancers and not (or
rarely) in healthy controls (Silva et al, 1999a, 1999b; Wong et al,
1999; Goessl et al, 2000; Sanchez-Cespedes et al, 2000; (c)
in general, a high concordance between epigenetic alterations in
primary tumour specimens and in blood has been reported
(Usadel et al, 2002; Hoque et al, 2004; Topaloglu et al, 2004; Yang
et al, 2004); (d) they are not limited to patients with metastatic
cancer, but are also present in body fluid from patients with early
or organ-confined tumours (Esteller et al, 1999; Sanchez-Cespedes
et al, 2000). As no single gene is known to be hypermethylated in
more than a proportion of breast tumours, it is necessary to use a
panel of genes to provide a target for detection in serum. We
selected three genes, namely, APC, RASSF1A and ESR1, which are
known to be frequently hypermethylated in breast cancer
(Widschwendter and Jones, 2002). We decided to measure
methylation levels of these genes in serum instead of plasma, as
Mu ¨ller et al (2003) indicated the prognostic relevance of
methylated DNA coding for these three genes in pre-therapeutic
serum samples of patients with primary breast cancer (Mu ¨ller et al
2003). Furthermore, to date, their remains no consensus as to
whether plasma or serum is better for the assessment of circulating
methylated DNA in cancer patients’ blood. Overall, 53% of breast
cancer patients showed hypermethylation of at least one of the
three genes. RASSF1A had the highest frequency of hypermethyla-
tion with 35% of breast cancer cases being positive, followed by
APC and ESR1 being methylated in 29 and 20% of breast cancer
cases, respectively. Methylation in serum DNA was never detected
if this alteration was not present in the primary tumour tissue. We
found no correlation between methylated DNA levels in serum and
corresponding levels in the primary tumour tissue. This could be
because of the specific physiological characteristics in the
progression of each tumour, for example, angiogenic capacity,
the ability to cause local necrosis (Usadel et al, 2002; Widsch-
wendter et al, 2004a). Alternatively, the quantity and quality of
DNA templates extracted from serum or the original primary
tumour can differ on the basis of time of collection, the content of
DNAse and other factors (Usadel et al, 2002; Widschwendter et al,
2004a) or the presence of normal DNA in blood may obscure
minute amounts of circulating tumour-related DNA.
Methylation was also detected in a small proportion of controls
(16%). Methylation of several genes has been reported earlier in
non-malignant tissues and serum DNA of smokers. Detection of
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Figure 7 Correlation between plasma total DNA levels and the number
of circulating tumour cells in the blood from breast cancer patients.
Figure 6 Images of circulating tumour cells from the CellTracks Analyzer
II obtained from 7.5ml of blood from breast cancer patients.
Table 5 (a) Correlation of plasma total DNA levels with CTC;
(b) correlation of serum methylated DNA with CTC
CTC
(a) Total DNA levels (ngml
 1)
Negative
(n¼52)
Positive
(n¼27) P-value
Median 10 31 0.002
Range 2–118 3–2027
CTC
(b) Methylated serum DNA
Negative
(n¼51)
Positive
(n¼27)
APC
Methylated 11 (48%) 12 (52%) 0.03
Unmethylated 40 (73%) 15 (27%)
RASSF1A
Methylated 10 (36%) 18 (64%) o0.001
Unmethylated 41 (82%) 9 (18%)
ESR1
Methylated 10 (62%) 6 (38%) 0.79
Unmethylated 41 (66%) 21 (34%)
Abbreviations: APC¼adenomatous polyposis coli; CTC¼circulating tumour cell;
ESR1¼oestrogen receptor 1; RASS1A¼ras association domain family protein 1A.
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smethylation in serum DNA could be a marker of disease (an early
neoplastic effect), exposure (a biological effect of any environ-
mental factor) or both (Hoque et al, 2006).
Our most interesting finding of correlating methylation data to
clinicopathological variables was the strong association between
methylation of RASSF1A in serum DNA and HR status. Methyla-
tion of RASSF1A in breast cancer has already been connected to
hormone regulation, but the mechanism is not clear yet.
Widschwendter et al. reported significant differences in the HR
status between clusters of DNA methylation profiles (Widsch-
wendter et al, 2004b). Feng et al. investigated whether methylation
of a set of growth-suppressor genes would correlate with the
expression of ER and PR, and found that methylation of RASSF1A
was strongly correlated with ER, PR and HR expression (Feng et al,
2007). Also in the study by Sunami et al., hypermethylation of
RASSF1A was more frequently present in ERþ breast tumours
than in ER– breast tumours (Sunami et al, 2008). Thus, it seems
that epigenetic alterations in the RASSF1A gene promoter and HR
regulation in breast cancer are tightly linked.
Using the CellSearch System, at least one positive cell was
identified in the blood of 65% of breast cancer patients and 10% of
controls. It has been reported that false positive results using
immuno-mediated CTC detection techniques can occur by specific
labelling of non-tumour epithelial cells or non-specific labelling of
non-tumour non-epithelial cells (Paterlini-Brechot and Benali,
2007). Variable numbers of epithelial cells have been found in
peripheral blood of subjects without malignancy, being related to
benign epithelial proliferative diseases, inflammation, tissue
trauma, semi-surgical and surgical interventions (Crisan et al,
2000; Goeminne et al, 2000; Fehm et al, 2005).
To date, there is no agreement on the mechanisms that are
responsible for the presence of tumour DNA shed into the
bloodstream. The most common hypothesis is the shedding of
lysed CTC. However, this seems to be unlikely because the number
of CTC is inadequate to explain the observed amount of DNA in
the plasma or serum (Stroun et al, 2000). Other possibilities are
that apoptosis and necrosis of tumour cells increase the levels of
circulating DNA (Jahr et al, 2001) or that DNA is actively released
into the bloodstream by the tumour (Stroun et al, 2000). In this
study, we observed a good association between total DNA or
tumour-specific DNA levels and the number of CTC in blood from
breast cancer patients. Patients with CTC in peripheral blood had
significantly higher plasma total DNA levels than patients with no
CTC. PMR values for APC and RASSF1A were significantly
correlated with the number of CTC detected in peripheral blood.
Furthermore, a combination assessment of these three molecular
markers could predict tumour progression. Similar findings to
ours have been reported earlier in patients with melanoma
(Koyanagi et al, 2006). Koyanagi et al. showed that the detection
of CTC was correlated with tumour-related methylated DNA and
that a combined assessment of both molecular markers improved
the assessment of prognosis in stage IV melanoma patients treated
with biochemotherapy. However, Schwarzenbach et al. did not
observe a correlation between the incidence of loss of hetero-
zygosity in circulating DNA and the presence of CTC in the blood
from breast cancer patients (Schwarzenbach et al, 2004). The
observed correlation between CTC and circulating methylated
DNA in our study could be interpreted in two ways: (a) CTC are a
potential source of circulating tumour-specific DNA; (b) high
numbers of CTC and circulating methylated DNA are both a
phenotypic feature of more aggressive tumour biology.
In conclusion, this study provides evidence that the detection of
large amounts of free circulating total DNA and of methylated
genes are associated with CTC in peripheral blood from patients
with advanced breast cancer. Furthermore, the combined assess-
ment of all three molecular markers was predictive for tumour
progression. However, large-scale studies are necessary to verify
the clinical utility of CTC and serum methylated DNA as potential
prognostic factors in breast cancer patients.
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